Roman Owens is the Founder and Chief Executive Officer of OncoVanta Therapeutics, where he leads the company’s strategic vision, partnerships, and translational oncology initiatives focused on advancing mutant p53-targeting TCR-T cell therapies. With a background bridging finance, engineering, and biotechnology, Roman brings a multidisciplinary perspective to biopharma leadership — combining business acumen with a strong understanding of scientific and operational execution.

Prior to founding OncoVanta, Roman served as Business Development Manager at Alphea Biopharma, where he drove growth in diagnostic and pharmaceutical partnerships, and as Senior Business Analyst at GEICO and Morgan Stanley, where he specialized in risk modeling, strategic planning, and data-driven decision support. Earlier in his career, he worked as a Control Systems Engineer at Bechtel Engineering, overseeing nuclear system design and compliance.

Roman holds an M.S. in International Financial Management from the University of Maryland Global Campus, a B.S. in Applied Physics from Frostburg State University, and an A.A.S. in Computer Programming and Networking from Monroe College.

At OncoVanta, he integrates business strategy with translational science to accelerate the company’s mission of developing next-generation TCR-T therapies that redefine cancer treatment.